Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

Abstract

The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been described. We analyzed outcomes of 275 MM patients at 14 academic centers with disease refractory to CD38 MoABs. Median interval between MM diagnosis and refractoriness to CD38 MoAB (T₀) was 50.1 months. The median overall survival (OS) from T₀ for the entire cohort was 8.6 [95% C.I. 7.5-9.9] months, ranging from 11.2 months for patients not simultaneously refractory to an immunomodulatory (IMiD) agent and a proteasome inhibitor (PI) to 5.6 months for "penta-refractory" patients (refractory to CD38 MoAB, 2 PIs and 2 IMiDs). At least one subsequent treatment regimen was employed after T₀ in 249 (90%) patients. Overall response rate to first regimen after T₀ was 31% with median progression-free survival (PFS) and OS of 3.4 and 9.3 months, respectively. PFS was best achieved with combinations of carfilzomib and alkylator (median 5.7 months), and daratumumab and IMiD (median 4.5 months). Patients with MM refractory to CD38 MoAB have poor prognosis and this study provides benchmark for new therapies to be tested in this population.

Figure 1–

OS of MM patients refractory to CD38 MoAB according to refractoriness to PIs and IMiDs (panel a), cytogenetic risk (panel b), LDH (panel c) and renal function (panel d) at time of initiation of index regimen.

Figure 2–

OS (panel a) and PFS (panel b) of MM patients refractory to CD38 MoAB therapy according to depth of response to next line of therapy.